PTC Therapeutics Inc

Insider sales at PTC Therapeutics reveal routine portfolio moves, not a warning—CEO sells 7,371 shares as earnings rebound outlook strengthens.

Mark Elliott’s fresh buy of PTC shares signals insider optimism ahead of Feb 19 earnings, hinting at confidence in the company’s pipeline and growth prospects.

PTC insider sales are routine tax‑cover events, not confidence shifts; investors should focus on Sephiencet approvals and pipeline progress.